In fiscal year 2024, KYUNG NAM PHARM (053950) reported revenue of 60.8 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2024 | 60.8 billion KRW | -943 million KRW | 8.6 billion KRW | [source] |
| 2023 | 68.4 billion KRW | -6.7 billion KRW | -22.2 billion KRW | [source] |
| 2022 | 59.0 billion KRW | -3.4 billion KRW | -6.8 billion KRW | [source] |
| 2021 | 64.6 billion KRW | -7.7 billion KRW | -3.4 billion KRW | [source] |
| 2020 | 70.9 billion KRW | 2.6 billion KRW | -5.5 billion KRW | — |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2024 | 166.4 billion KRW | 51.3 billion KRW | 115.1 billion KRW | [source] |
| 2023 | 141.0 billion KRW | 57.3 billion KRW | 83.7 billion KRW | [source] |
| 2022 | 144.6 billion KRW | 44.4 billion KRW | 100.2 billion KRW | [source] |
| 2021 | 125.1 billion KRW | 52.2 billion KRW | 72.9 billion KRW | [source] |
| 2020 | — | — | — | — |
Years without a source link are outside the DART financial API collection period.
Balance sheet figures for the relevant year were not collected.